Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the second-highest quintile among peers.
Rydex Health Care Inv RYHIX
- NAV / 1-Day Return 44.09 / +0.66 %
- Total Assets 24.1 Mil
-
Adj. Expense Ratio
- Expense Ratio 1.390%
- Distribution Fee Level Above Average
- Share Class Type No Load
- Category Health
- Investment Style Large Blend
- Min. Initial Investment 2,500
- Status Open
- TTM Yield —
- Turnover 116%
USD | NAV as of Jul 26, 2024 | 1-Day Return as of Jul 26, 2024, 10:17 PM GMT+0
Morningstar’s Analysis RYHIX
Will RYHIX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings —
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Eli Lilly and Co | 4.27 | 986,049 | Healthcare |
UnitedHealth Group Inc | 3.44 | 793,087 | Healthcare |
Johnson & Johnson | 2.89 | 666,468 | Healthcare |
Merck & Co Inc | 2.85 | 656,825 | Healthcare |
AbbVie Inc | 2.55 | 588,526 | Healthcare |
Thermo Fisher Scientific Inc | 2.28 | 525,382 | Healthcare |
Amgen Inc | 2.18 | 502,817 | Healthcare |
Danaher Corp | 2.11 | 486,636 | Healthcare |
Pfizer Inc | 2.10 | 484,755 | Healthcare |
Abbott Laboratories | 1.93 | 446,264 | Healthcare |